Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2024-04-09 07:00:15
Oslo, Norway, 9 April 2024 - Circio Holding ASA (OSE: CRNA): Circio's management
invites to a company update hosted by Redeye on Wednesday 17 April at 8am CEST.
In the webcast, CEO Erik Digman Wiklund will provide an overview of the latest
circVec circular RNA platform in vivo data and the focused gene therapy R&D
strategy, and CFO Lubor Gaal will present unaudited financial results for 2023.
Following the presentation, there will be a Q&A session with RedeyeŽs equity
research analyst Richard Ramanius.
Date: Wednesday 17 April 2024
Time: 8:00am CEST
Watch: Available on demand via circio.com
and redeye.se (link provided on the
day)
Presenters: Dr. Erik Digman Wiklund, Chief
Executive Officer (CEO)
Dr. Lubor Gaal, Chief Financial
Officer (CFO)
Questions can be submitted in advance until 18:00 CEST on Monday 15 April in
English, Norwegian and Swedish, and will be addressed in the respective
language.
Submit your questions to CFO Lubor Gaal by email: lubor.gaal@circio.com
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)
About Circio
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for rare disease, vaccines, and cancer. The proprietary
circVec technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA from DNA and viral vectors, which can be
deployed for many purposes. The circVec platform has demonstrated enhanced and
more durable protein expression than classic mRNA vector systems, and has the
potential to become the new gold-standard for DNA and virus-based therapeutics
in the future. The circRNA R&D activities are being conducted by the wholly
owned subsidiary Circio AB based at the Karolinska Institute in Stockholm,
Sweden.
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.